Glaxo Exits Cancer Drugs
Glaxo to Focus on Respiratory and HIV Treatments, Vaccines, Consumer-Health Products
Updated April 22, 2014 8:19 a.m. ET
LONDON—GlaxoSmithKline PLC's decision to leave the hot field of
cancer drugs narrows the focus of its business to just four areas:
respiratory and HIV treatments, vaccines and consumer-health products.
The move, included in a series of transactions announced Tuesday that will reshape both Glaxo and Novartis AG, is part of a trend for pharmaceutical companies to focus on a handful of "core disease areas" to gain scale and...
The move, included in a series of transactions announced Tuesday that will reshape both Glaxo and Novartis AG, is part of a trend for pharmaceutical companies to focus on a handful of "core disease areas" to gain scale and...
沒有留言:
張貼留言